Literature DB >> 20044029

Hyperforin induces Ca(2+)-independent arachidonic acid release in human platelets by facilitating cytosolic phospholipase A(2) activation through select phospholipid interactions.

Marika Hoffmann1, Jakob J Lopez, Carlo Pergola, Christian Feisst, Sven Pawelczik, Per-Johan Jakobsson, Bernd L Sorg, Clemens Glaubitz, Dieter Steinhilber, Oliver Werz.   

Abstract

Here, we investigated the modulation of cytosolic phospholipase A(2) (cPLA(2))-mediated arachidonic acid (AA) release by the polyprenylated acylphloroglucinol hyperforin. Hyperforin increased AA release from human platelets up to 2.6 fold (maximal effect at 10microM) versus unstimulated cells, which was blocked by cPLA(2)alpha-inhibition, and induced translocation of cPLA(2) to a membrane compartment. Interestingly, these stimulatory effects of hyperforin were even more pronounced after depletion of intracellular Ca(2+) by EDTA plus BAPTA/AM. Hyperforin induced phosphorylation of cPLA(2) at Ser505 and activated p38 mitogen-activated protein kinase (MAPK), and inhibition of p38 MAPK by SB203580 prevented cPLA(2) phosphorylation. However, neither AA release nor translocation of cPLA(2) was abrogated by SB203580. In cell-free assays using liposomes prepared from different lipids, hyperforin failed to stimulate phospholipid hydrolysis by isolated cPLA(2) in the presence of Ca(2+). However, when Ca(2+) was omitted, hyperforin caused a prominent increase in cPLA(2) activity using liposomes composed of 1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphoethanolamine but not of 1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphocholine (PAPC) unless the PAPC liposomes were enriched in cholesterol (20 to 50%). Finally, two-dimensional (1)H-MAS-NMR analysis visualized the directed insertion of hyperforin into POPC liposomes. Together, hyperforin, through insertion into phospholipids, may facilitate cPLA(2) activation by enabling its access towards select lipid membranes independent of Ca(2+) ions. Such Ca(2+)- and phosphorylation-independent mechanism of cPLA(2) activation may apply also to other membrane-interfering molecules. 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20044029     DOI: 10.1016/j.bbalip.2009.12.007

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  3 in total

1.  Molecular pharmacological profile of a novel thiazolinone-based direct and selective 5-lipoxygenase inhibitor.

Authors:  B Hofmann; C B Rödl; A S Kahnt; T J Maier; A A Michel; M Hoffmann; O Rau; K Awwad; M Pellowska; M Wurglics; M Wacker; A Zivković; I Fleming; M Schubert-Zsilavecz; H Stark; G Schneider; D Steinhilber
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

2.  Elucidation of the molecular mechanism and the efficacy in vivo of a novel 1,4-benzoquinone that inhibits 5-lipoxygenase.

Authors:  A M Schaible; R Filosa; V Temml; V Krauth; M Matteis; A Peduto; F Bruno; S Luderer; F Roviezzo; A Di Mola; M de Rosa; B D'Agostino; C Weinigel; D Barz; A Koeberle; C Pergola; D Schuster; O Werz
Journal:  Br J Pharmacol       Date:  2014-05       Impact factor: 8.739

3.  R-Flurbiprofen Traps Prostaglandins within Cells by Inhibition of Multidrug Resistance-Associated Protein-4.

Authors:  Ivonne Wobst; Lisa Ebert; Kerstin Birod; Marthe-Susanna Wegner; Marika Hoffmann; Dominique Thomas; Carlo Angioni; Michael J Parnham; Dieter Steinhilber; Irmgard Tegeder; Gerd Geisslinger; Sabine Grösch
Journal:  Int J Mol Sci       Date:  2016-12-30       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.